Information Provided By: 
Fly News Breaks for July 17, 2015
ANGO
Jul 17, 2015 | 07:35 EDT
Canaccord said the recent dip in AngioDynamics should be considered a buying opportunity for value-oriented small-cap investors, as the firm expects improving margins and free cash flow generation over the next few years. Canaccord lowered its price target to $19 form $20 on AngioDynamics shares and reiterated its Buy rating.
News For ANGO From the Last 2 Days
There are no results for your query ANGO
